Argus
•
May 27, 2026
Viatris Inc.: Raising target price to $18
Summary
Viatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer’s Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has approximately 30,000 employees.
Viatris has scientific, manufacturing, distribution, and regulatory expertise, and serves patients in more than 165 countries and territories. The company’s portfolio includes more than 1,300 approved molecules across a wide range of therape
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus’ bespoke research on IPOs.
